Partnership for Sustainable Textiles Recognizes U.S. Cotton Trust Protocol as a Standard for Sustainable Cotton
13.6.2022 15:32:00 EEST | Business Wire | Press release
The U.S. Cotton Trust Protocol has been approved as a standard for sustainable cotton by Siegelklarheit, an initiative of the German Federal Government. By helping consumers to better understand environmental and social labels, Siegelklarheit wants to contribute to more sustainable purchasing decisions. U.S. Cotton Trust Protocol successfully passed Siegelklarheit´s assessment system. As a result, members of the Partnership for Sustainable Textiles (PST) can use the Trust Protocol as another standard to calculate their share of sustainable cotton.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220613005297/en/
U.S. Cotton Trust Protocol (Photo: Business Wire)
The Partnership for Sustainable Textiles was founded in October 2014, with the mission to improve social and ecological conditions within global textile supply chains. The Textiles Partnership orientates its work on the OECD Due Diligence Guidance and on international agreements and guidelines that define the principles of social, environmental, and economic sustainability and the framework for corporate responsibility.
“Members of the Partnership for Sustainable Textiles work together to achieve substantial social and ecological improvements in their global supply chains,” said Jürgen Janssen, head of the PST secretariat. “This also includes the production of raw materials and thus the cultivation and processing of cotton. In the Textiles Partnership, we advocate for transparent and traceable criteria in the certification of sustainable cotton. We are pleased that the Trust Protocol has successfully passed the audit by Siegelklarheit.”
The PST has developed an implementation framework and reporting format for corporate due diligence. In the context of this format PST member companies also indicate how much cotton they source and how much of it is sustainable or organic cotton, certified by recognized standards. Besides U.S. Cotton Trust Protocol, these include Better Cotton standard, the Australian myBMP standard, Cotton made in Africa, Fairtrade Cotton and CottonConnect. The following standards apply to purchasing of organic cotton: the Global Organic Textile Standard (GOTS), the International Association of Natural Textile Industry (NATURTEXTIL IVN) standard, the Textile Exchange Organic Content Standard (OCS), the bioRe Social & Environmental Standard, and all the organic standards forming part of the IFOAM Family of Standards.
The Trust Protocol is the only system that provides quantifiable, verifiable goals and measurement and drives continuous improvement in six key sustainability metrics - land use, soil carbon, water management, soil loss, greenhouse gas emissions, and energy efficiency. It is also the world’s first sustainable cotton fiber to offer its members article-level supply chain transparency through the Protocol Consumption Management Solution.
“We are thrilled to have received this recognition of being a sustainable cotton standard by the Partnership for Sustainable Textiles and proud to have passed Siegelklarheit’s rigorous assessment,” said Dr. Gary Adams, president of the U.S. Cotton Trust Protocol. “The Trust Protocol’s vision is to set a new standard in sustainable cotton production where full transparency is a reality and continuous improvement to reduce our environmental footprint is the central goal. We commit to ensuring the protection and preservation of the planet, using the most sustainable and responsible techniques.”
The U.S. Cotton Trust Protocol is aligned with the UN Sustainable Development Goals, recognized by Textile Exchange and Forum for the Future, and part of the Sustainable Apparel Coalition, Cotton 2025 Sustainable Cotton Challenge, Cotton 2040 and Cotton Up initiatives. It has also been recognized and published in the ITC Standards Map.
To learn more about the U.S. Cotton Trust Protocol visit TrustUSCotton.org.
About the U.S. Cotton Trust Protocol
Launched in 2020, the U.S. Cotton Trust Protocol was designed to set a new standard in more sustainably grown cotton, ensuring that it contributes to the protection and preservation of the planet, using the most sustainable and responsible techniques. It is the only farm level, science-based program that provides quantifiable, verifiable goals and measurement in six key sustainability metrics as well as article-level supply chain transparency.
The Trust Protocol is overseen by a multi-stakeholder Board of Directors comprised of representatives from brands and retailers, civil society, and independent sustainability experts as well as the cotton-growing industry, including growers, ginners, merchants, wholesalers and cooperatives, mills, and cottonseed handlers.
About the Partnership for Sustainable Textiles
The Partnership for Sustainable Textiles (PST) is committed to a socially, ecologically, and corruption-free textile and garment industry – an industry that respects the rights of all workers, that protects the climate and the environment, and operates with integrity and within planetary boundaries. The Textiles Partnership aligns its work on international agreements and guidelines that define the principles of social, environmental, and economic sustainability and set the framework for corporate responsibility. The objectives of the PST concerning social and human rights issues are based in particular on the ILO Conventions, the UN Principles on Business and Human Rights, and the OECD Guidelines for Multinational Enterprises. In implementing its goals, the Partnership is strongly oriented towards the recommendations of the OECD. In order to achieve its goals, the PST places a special focus on the implementation of corporate due diligence and responsible business conduct in Germany, Europe and worldwide.
Website: https://www.textilbuendnis.com/en
Visit us online at TrustUSCotton.org.
Follow us at:
https://twitter.com/trustuscotton
https://www.facebook.com/trustuscotton/
https://www.instagram.com/trustuscotton/
https://www.linkedin.com/company/responsibleuscotton/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220613005297/en/
Contact information
Media: Andrea Miles, andrea.miles@hkstrategies.com, +1 (213) 400-8267
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
